Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. Its products include original medicine such as Chidamide, Chiglitazar, Chiauranib. It also engages in technological licensing. The company was founded by Xian Ping Lu and Zhi Qiang Ning on March 21, 2001 and is headquartered in Shenzhen, China.

Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.\nIn line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Kancera AB engages in the research, development and sale of drug candidate to pharmaceutical companies. Its portfolio includes Fractalkine, ROR inhibitors, HDAC6 and PFKFB3 projects. The company was founded by Hakan Mellstedt on April 28, 2010 and is headquartered in Solna, Sweden.

AXYS Pharmaceuticals, Inc. is engaged in discovery, design, and development of therapeutic small molecules that addressed significant markets with major unmet medical needs. It collaborates with large pharmaceutical companies in discovering therapeutics for chronic diseases. In addition, it also discovers and develops therapeutics for the treatment of various types of cancer and other specialty therapeutic opportunities. AXYS Pharmaceuticals, Inc. was formerly known as Arris Pharmaceuticals, Incorporated. The company is based in South San Francisco, California. As of November 16, 2001, AXYS Pharmaceuticals, Inc. operates as a subsidiary of Celera Corporation.

HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. It offers DEL screening and library customization, chemical synthesis, and new drug research and development project transfer services. The company was founded by Jin Li on February 22, 2012 and is headquartered in Chengdu, China.

MEI Pharma is a oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

As a world leading cancer care company they aim to improve the health and quality of life for every person with cancer - today, now, when it counts. Their vision is to help people with cancer get the most of every day. As one of the world's leading cancer care companies, their goal is to make everything they do, from the products they choose to license to the quality standards they apply to manufacturing, count towards improving the lives of people with cancer.

CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada.

Repligen Corporation is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating Tangential Flow) systems and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an innovative line of “ready-to-use” chromatography columns under our OPUS® and MediaScout® brands that we deliver pre-packed with our customers’ choice of resin. Repligen’s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Lund, Sweden and Weingarten, Germany.

G2M Cancer Drugs AG, part of Onxeo SA, is a German company located in Frankfurt am Main focused on commercial physical and biological research. On March 01, 2005 Topotarget An acquired G2M Cancer Drugs AG.

Their mission is to identify innovative research in life science and to develop novel therapies and tools by creating successful business initiatives in a sustained and long term way. Genextra's holding structure is designed to increase the probability of success of business initiatives that become part of the Group by providing specialist management as well as financial support to a new company vehicle or an existing young start-up. Genextra was created in 2004 by a group of prominent Italian entrepreneurs and financial institutions in partnership with leading scientists from the European Institute of Oncology (IEO). To date, Genextra has raised over €116 million and represents one of very few examples in Italy of private capital invested for the benefit of research and innovation.

4SC AG is a clinical-stage biopharmaceutical company, which engages in the development of small molecule drugs that target key indications in cancer. Its product pipeline includes resminostat and domatinostat. The company was founded by Stefan Busemann, Ulrich Dauer, Klaus-Peter Gulden, and Daniel Vitt in 1997 and is headquartered in Planegg-Martinsried, Germany.

AnnJi Pharmaceutical is a clinical-stage drug development company that specializes in developing small molecules that address unmet medical needs in the areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, and SBMA (Spinal and bulbar muscular atrophy). The focus of the company is on creating global collaborations and business partnerships in the late-stage product development and commercialization of pharmaceutical drugs.

Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. The company was founded by Xi Juan Wang and Jian Hua Liu on September 3, 2003 and is headquartered in Beijing, China.

Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetic, antivirus, beta-blocking, anti-hyperlipidemia and others. The company was founded on November 5, 2013 and is headquartered in Seoul, South Korea.